Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES

• ClinicalTrials.gov Identifier: NCT03399994
• Recruitment Status: Active, not recruiting
• First Posted: January 17, 2018
• Last Update Posted: March 29, 2022
• Sponsor: Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
• Collaborator: Mediolanum Cardio Research
• Information provided by (Responsible Party): Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS

Study Description

Brief Summary:

The objective of the study is to compare angiographic and clinical performance of Abluminus DES+ versus Everolimus-eluting DES in patients with diabetes mellitus.

Condition or disease	Intervention/treatment	Phase
Coronary Artery Disease; Diabetes	Device: device implantation during coronary angioplasty	Not Applicable

Detailed Description:

The present clinical investigation is designed as a prospective, multicentre, national, randomized, open label, 2-arm parallel group, pilot trial comparing Abluminus DES+ versus Everolimus-eluting DES on Late Lumen Loss and clinical outcomes in diabetic patients undergoing Percutaneous Coronary Intervention.

A total of 165 patients will be recruited and randomized in the two groups in a 2:1 ratio at up to 6-8 Italian sites.

After index procedure, patients will be followed up by angiographic follow-up at 9 months and clinical follow-up at 12 months.

The study design is open label, since it is not possible to blind the investigators as to the stent type. However the members of the Event Adjudication Committee will be blinded to the patient. assignment. All medical records, source documentation and event information collected for the adjudication process will be blinded to treatment assignment.

In addition the primary endpoint will be independently evaluated by the Core-Lab which will be blinded as to group assignment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 137 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Randomized multi-centre controlled clinical trial
• Masking: Single (Outcomes Assessor)
• Masking Description: The members of the Event Adjudication Committee will be blinded to the patient assignment. All medical records, source documentation and event information collected for the adjudication process will be blinded to treatment assignment
• Primary Purpose: Treatment
• Official Title: A Randomized Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES for Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: an Investigator-initiated Pilot Study
• Actual Study Start Date: May 21, 2018
• Actual Primary Completion Date: April 15, 2021
• Estimated Study Completion Date: June 30, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: ABLUMINUS DES+; device implantation during coronary angioplasty	Device: device implantation during coronary angioplasty; device implantation during coronary angioplasty
Active Comparator: Everolimus-eluting DES; device implantation during coronary angioplasty	Device: device implantation during coronary angioplasty; device implantation during coronary angioplasty

Outcome Measures

Primary Outcome Measures :

1. In-stent neointimal volume [ Time Frame: 9-month follow-up ]
   In-stent neointimal volume, measured with OCT, following PCI with Abluminus DES+ compared with in-stent neointimal volume following PCI with Everolimus-eluting DES.

Secondary Outcome Measures :

1. Neointimal area [ Time Frame: 9-month follow-up ]
   Neointimal area, calculated at the site of minimal lumen area measured with OCT.
2. Target Lesion Failure [ Time Frame: 12 months ]
   This will be a composite of cardiac death, target-vessel MI, and clinically indicated TLR
3. Stent thrombosis [ Time Frame: 12 months ]
   This is defined according to classification proposed by the Academic Research Consortium
4. Cardiac death [ Time Frame: 12 months ]
   Any death due to proximate cardiac cause (eg, MI, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death.
5. Target vessel myocardial infarction [ Time Frame: 12 months ]
   Any MI that, irrespective of the time after the index procedure, is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause33 Type of acute MI is classified according to the Joint ESC/ACCF/AHA/ WHF Joint Task Force for the Universal Definition of Myocardial Infarction
6. Target lesion revascularization [ Time Frame: 12 months ]
   repeat revascularization will be defined as any repeat PCI or new coronary artery bypass graft (CABG) surgery within the first year post-PCI.
7. Device success at 24 hours [ Time Frame: 24 hours ]
   deployment of the assigned stents without system failure or device-related complication
8. Lesion success [ Time Frame: 24 hours ]
   Attainment of <50% residual stenosis of the target lesion using post-PCI
9. Procedural success [ Time Frame: 24 hours ]
   Lesion success without the occurrence of Major Adverse Cardiac Events during the hospital stay

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age>18
2. Diabetes mellitus
3. Documented CAD: stable or unstable angina, Non-ST segment MI, silent ischemia or positive functional study
4. PCI considered appropriate and feasible
5. Culprit de novo lesion in a native coronary artery with significant stenosis (>50% by visual estimate) eligible for stent implantation (no limitation on the number of treated lesions, vessel and lesion length);
6. Patient provides written informed consent
7. Patient agrees to all required follow-up procedures and visits.
8. Target lesion suitable for PCI with DES diameter between 2.5 and 4.0 mm.

Exclusion Criteria:

1. The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, ticlopidine, sirolimus, everolimus, and/or contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled);
2. Any contraindication to the implant of the Abluminus DES+
3. Subject is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or does not consistently use effective methods of contraception;;
4. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions;
5. Previous coronary intervention on target vessel in the 3-months prior to enrollment;
6. Non-cardiac co-morbid conditions with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment);
7. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period;
8. Previously documented left ventricular ejection fraction (LVEF) <30%;
9. Evident cardiogenic shock before randomization;
10. Patients with left main stem stenosis (>50% by visual estimate);
11. In-stent restenosis;
12. ST-segment elevation MI;
13. Chronic total occlusion.
14. Culprit lesion to a Saphenous Vein graft

Contacts and Locations

Locations

Italy

Ospedale San Raffaele

Miano, Milano, Italy, 20132

Ospedale Humanitas

Rozzano, Milano, Italy, 20089

Policlinico San Donato

San Donato Milanese, Milano, Italy, 20097

Azienda Ospedaliero Universitaria Policlinico Federico II

Napoli, Italy, 20131

Policlinico S. Matteo

Pavia, Italy, 27100

Ospedale San Pietro, Fatebenefratelli

Roma, Italy, 00189

Sponsors and Collaborators

Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS

Mediolanum Cardio Research

Investigators

• Study Director: Antonio Colombo, MD; Ospedale San Raffaele
• Principal Investigator: Azeem Latib, MD; Ospedale San Raffaele

More Information

• Responsible Party: Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
• ClinicalTrials.gov Identifier: NCT03399994
• Other Study ID Numbers: ABILITY
• First Posted: January 17, 2018
• Last Update Posted: March 29, 2022
• Last Verified: March 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Coronary Artery Disease; Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases